NCT00004941View on ClinicalTrials.gov

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

July 31, 1996

Study Completion Date

July 31, 1996

Conditions
Crohn's Disease
Interventions
DRUG

monoclonal antibody cA2

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

FDA Office of Orphan Products Development

FED

NCT00004941 - Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease | Biotech Hunter | Biotech Hunter